Know the cure, take the lead.
In general, we consider that a clinical cure has been achieved if, after treatment, patients with breast cancer no longer find tumour tissue in their bodies and the indicators are normal, and if there is no local relapse or remote transfer for five years. This is not to say that the treatment of breast cancer is only five years old, but it is because the two years after the patient ‘ s roots are often the peak of tumour recurrence, and if it remains after five years, the risk of future reoccurrence is lower. So, to achieve a cure, the future is infinite! Early treatment is the key to the cure of breast cancer! The sooner we find out, the sooner we treat them, the higher the cure rate! Early breast cancer can be cured by more than 90%! As a rule, doctors perform standard classification of diseases according to the original tumour size of breast cancer patients (T), regional lymphorate transfer (N) and remote transfer (M).[2] In short, the smaller the original tumour of the patient, the less the lymph nodes are transferred or not, the less the organs are transferred or not transferred far away, and the earlier the patient is divided. However, the size and transfer of tumours does not provide a full basis for predicting the prognosis of breast cancer patients. The molecular stratification of breast cancer is also one of the important signs in the patient ‘ s healing journey. The hormonal receptor (HR) positive breast cancer, which accounts for more than 70 per cent of all breast cancers, not only accounts for a high percentage of this type of tumour, but also for a slower rate of disease, a lower intrusiveness, access to endocrinological treatment and better survival.
New Auxiliary Care, sounding the cholesterol.
The treatment of this guy with the tumor is a good cure for the root. But before they are removed, patients may face problems, such as the early stages, the tumour tissues, and the difficulty of removing them. In this case, the patient needs help with new assisted treatment – i.e., before the operation, the tumours in the patient’s body are reduced, the disease is reduced, thus creating more favourable conditions for subsequent surgical removal, and the opportunity for the patient to retain a breast. According to the 2023 edition of the Chinese Society for Clinical Oncology (CSCO) guidelines for breast cancer [3], new assistive treatment may be considered for patients with HIV positive breast cancer, with breast > 5 cm or with lymphoma transfer. In the case of HIV positive breast cancer, the main new assistive treatment is chemotherapy, and new assistive endocrine treatment is available to patients who are not fit for chemotherapy or temporary inoperable surgery, and the most common endocrine drug for breast cancer patients is aromatic enzyme inhibitor (AI), on the basis of which pre-menopausal patients are required to combine ovarian functional inhibition (OFS). Locally advanced patients who need some of the new assistive treatment may also be considered for a combination of the drug CDK4/6 inhibitor based on genocrine treatment. For new assisted endocrine treatments, effective and patient, sustainable treatment for six months. After completion of the new assisted treatment, the patient can undergo a subsequent surgical removal. If the tumor is seen as a bandit in the patient’s body, then the new auxiliary treatment is like a siege of the enemy and, through drug treatment, minimizes the range of operations until the operation starts and ends with the total elimination!
Surgeon ectoplasmic.
The operation is a crucial step for the patient to remove the tumor! Whether or not new and assisted treatment has previously been required, whether it has been chemotherapy or endocrine treatment, the presence of the operation is difficult to miss during the treatment of breast cancer. At present, breast cancer surgery can be divided into three main categories [4]:
Breastfeeding: Breast cancer patients who satisfy the lactation certificate should be the first to have breast milk. Because milking is comparable to, and even benefits from, whole-milk excision, patients retain their breast form while removing tumours, with higher levels of satisfaction.
Total mastectomy: The removal of tumours is the basis for breast cancer treatment and, if the patient is not able to reach the conditions for breast protection, breast mutilation is required. In the context of ensuring the safety of the operation, the retention of nipples, irradiation and breast skin mastectomy can provide the basis for subsequent breast rehabilitation operations.
Post-embracing rehabilitation: Breast-rehabilitation is the main means of re-establishing beauty for those who lack breast protection. Common methods of breast rehabilitation include breast replanting of implants, self-organizing breast redevelopment, and joint self-rehabilitation of implants.
Turn to the future train. Keep going.
Auxiliary treatment, by definition, is like a good assistant who consolidates the effects of the surgery, keeping a state of alert inside the body and preventing the re-emergence of the defunct tumor. Assistive treatment for patients with positive breast cancer in HR is dominated by endocrine treatment, and the target drug CDK4/6 inhibitor also plays an important role in assisted treatment for patients with breast cancer. Standardized treatment can provide a defence to life, and it is hoped that all breast cancer patients will not lose faith in life. Not only are early breast cancer curable, but even at an advanced stage, many breast cancer patients are able to sustain stable long-term tumours under regulatory control. At present, many clinical studies on innovative breast cancer therapy, such as the forward-to-target application of drugs, are also under way, and there is reason to believe that the future path of breast cancer patients must be broader.
References
Siegel RL, Miller KD, Fuchs HE, et al. Cancel Statistics, 2021 [J]
[2] Amin MB, Edge SB, Greene FL, et al. AJCC cancer moving human.
[3] China Society for Clinical Oncology (China Society for Clinical Oncology) Steering Committee.
[4] Li Pei, Wu Xian. Status and New Trends in Breast Cancer Surgery in China [J]. China Oncology Clinic, 2022, 49(22): 1151-1155.
Breast cancer
